An auto-generated ADP-ribosyl-cysteine degron drives DTX2-dependent turnover of PARP7
The mono-ADP-ribosyltransferase PARP7 exerts negative feedback on androgen receptor (AR) signaling by generating an ADP-ribosyl-cysteine degron on AR that marks it for degradation. Here we show that the protein half-life of PARP7 is set by cysteine auto-ADP-ribosylation, providing a mechanism for temporal control of its feedback on AR-dependent transcription in prostate cancer cells. ADP-ribosyl-cysteine in the PARP7 catalytic domain constitutes a degron read by the E3 ligase DTX2, driving PARP7 polyubiquitination and proteasomal degradation. Thus, the same E3 is used to degrade both PARP7 and its substrate AR. Using label-free mass spectrometry, we identify the AP-1 factor c-JUN as a PARP7 substrate and show that ADP-ribosylated c-JUN accumulates upon DTX2 depletion. ADP-ribosyl degron formation is dependent on NAD+ availability since depleting NAD+ pharmacologically or under hypoxia prevents degron formation and stabilizes PARP7 in a catalytically constrained state that compromises its feedback activity. Correlations between PARP7 expression and hypoxia signatures in prostate tumors, together with sensitivity to the PARP7-selective inhibitor RBN-2397 across cancer lines, nominate hypoxic, NAD+ depleted contexts as heightened vulnerability to PARP7-targeting agents. Marking transcription factors for degradation by covalent ADP-ribosylation is emerging as a distinct mode of transcriptional control.
Authors
- Aakrosh Ratan (ORCID: https://orcid.org/0000-0002-0782-3056)
- Sara Charlotte Buch-Larsen (ORCID: https://orcid.org/0000-0001-6250-5467)
- Chunsong Yang (ORCID: https://orcid.org/0009-0002-9770-5594)
- Jesper Velgaard Olsen (ORCID: https://orcid.org/0000-0002-4747-4938)
- Bryce M. Paschal (ORCID: https://orcid.org/0000-0001-8593-0503)
- Hyukjin Jang (ORCID: https://orcid.org/0000-0002-3695-2666)
- Krzysztof Wierbiłowicz (ORCID: https://orcid.org/0000-0002-6896-7846)
- James Mitchell Larner (ORCID: https://orcid.org/0000-0002-8679-7772)
- Michael Lund Nielsen (ORCID: https://orcid.org/0000-0002-4226-6953)
- Thomas L. Genetta (ORCID: https://orcid.org/0000-0001-7254-7206)
- Grant R Diefenderfer
- Joshua S Wu
Institutions
- University of Copenhagen (DK)
- University of Virginia Medical Center (US)
- University of Virginia (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-10-28
- DOI
- https://doi.org/10.64898/2026.10.26.761924
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- preprint